Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy

Journal of Magnetic Resonance Imaging

Volumn 42, Issue 3, 2015, Pages 779-787

  Liu, Shangang ^a   Ren, Ruimei ^a   Chen, Zhaoqiu ^a   Wang, Yongsheng ^a   Fan, Tingyong ^a   Li, Chengli ^b   Zhang, Pinliang ^a  

^a UNIVERSITY OF JINAN   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

breast cancer subtype; diffusion weighted imaging; magnetic resonance imaging; neoadjuvant chemotherapy; pathological response

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ALKYLATING AGENT;

ADULT; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; AGED; BREAST; BREAST NEOPLASMS; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DIFFUSION MAGNETIC RESONANCE IMAGING; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84939272133     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24843     Document Type: Article

References (30)

1. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L,. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19: 4224-4237.
2. Desmedt C, Haibe-Kains B, Wirapati P, et al., Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14: 5158-5165.
3. Huober J, von Minckwitz G, Denkert C, et al., Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124: 133-140.
4. de Ronde JJ, Hannemann J, Halfwerk H, et al., Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010; 119: 119-126.
5. Rouzier R, Perou CM, Symmans WF, et al., Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
6. Hamstra DA, Rehemtulla A, Ross BD,. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25: 4104-4109.
7. Sharma U, Danishad KK, Seenu V, Jagannathan NR,. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009; 22: 104-113.
8. Park SH, Moon WK, Cho N, et al., Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010; 257: 56-63.
9. Jensen LR, Garzon B, Heldahl MG, Bathen TF, Lundgren S, Gribbestad IS,. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients. J Magn Reson Imaging 2011; 34: 1099-1109.
10. Kim SH, Cha ES, Kim HS, et al., Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging 2009; 30: 615-620.
11. Jeh SK, Kim SH, Kim HS, et al., Correlation of the apparent diffusion coefficient value and dynamic magnetic resonance imaging findings with prognostic factors in invasive ductal carcinoma. J Magn Reson Imaging 2011; 33: 102-109.
12. Martincich L, Deantoni V, Bertotto I, et al., Correlations between diffusion-weighted imaging and breast cancer biomarkers. Eur Radiol 2012; 22: 1519-1528.
13. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M,. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161: 401-407.
14. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ,. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
15. Ogston KN, Miller ID, Payne S, et al., A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003; 12: 320-327.
16. Loo CE, Straver ME, Rodenhuis S, et al., Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011; 29: 660-666.
17. Richard R, Thomassin I, Chapellier M, et al., Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol 2013; 23: 2420-2431.
18. Black R, Prescott R, Bers K, Hawkins A, Stewart H, Forrest P,. Tumor cellularity, estrogen receptors and prognosis in breast cancer. Clin Oncol 1983; 9: 311-318.
19. Ludovini V, Sidoni A, Pistola L, et al., Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 2003; 81: 159-168.
20. Makkat S, Luypaert R, Stadnik T, et al., Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings-preliminary results. Radiology 2008; 249: 471-482.
21. Perou CM, Sorlie T, Eisen MB, et al., Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
22. Elsawaf Z, Sinn HP,. Triple-negative breast cancer: clinical and histological correlations. Breast Care (Basel) 2011; 6: 273-278.
23. Uematsu T, Kasami M, Yuen S,. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009; 250: 638-647.
24. Desmedt C, Haibe-Kains B, Wirapati P, et al., Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14: 5158-5165.
25. Jung SH, Heo SH, Kim JW, et al., Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging. J Magn Reson Imaging 2012; 35: 110-116.
26. Mardor Y, Roth Y, Ochershvilli A, et al., Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 2004; 6: 136-142.
27. Koh DM, Scurr E, Collins D, et al., Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coef?cients. AJR Am J Roentgenol 2007; 188: 1001-1008.
28. Harrison L, Blackwell K,. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004; 9: 31-40.
29. von Minckwitz G, Raab G, Caputo A, et al., Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23: 2676-85.
30. Bear HD, Anderson S, Smith RE, et al., Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006; 24: 2019-2027.